KEAP1 mutations activate the NRF2 pathway to drive cell growth and migration, and attenuate drug response in thyroid cancer
Nicholas E. Bambach, Julio C. Ricarte‐Filho, Erin Renée Reichenberger…·Aime T. Franco
This study identifies KEAP1 mutations in thyroid cancer, showing they activate the NRF2 pathway, promote cell growth and migration, and reduce drug response.